Skip to main content

Table 3 Theoretical HIV isolate coverage provided by different vaccine trial responders.

From: Defining epitope coverage requirements for T cell-based HIV vaccines: Theoretical considerations and practical applications

  

Subject 1

  

Subject 2

 
 

Gag

Env

Total

Gag

Env

Total

Number of Epitopes

2

4

6

1

1

2

Intra-subtype Coverage

81.1%

85.8%

97.3%

56.6%

38.6%

73.4%

(CRF01_AE)

      

Global Group M Coverage

41.8%

44.5%

67.7%

23.7%

13.7%

34.1%

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us